9 & 10 May 2014 | New York, NY

  • skyline



  • impact id
9 - 10 May 2014 | Hudson Theatre @ Millennium Broadway, NYC

3rd Annual CME Symposium

This advanced continuing medical education activity, once again being held at the historic Hudson Theatre in New York City, will provide participants with state-of-the-art education and practical guidance from nationally and internationally recognized experts on hepatitis C virus infection.

The primary goals of this activity are to increase each frontline care provider's competence in:

  • •  Recognition of the indications for treatment of HCV infection
  • •  Assessment of disease manifestations, stage and prognosis
  • •  Formulation of individualized care plans
  • •  Application of new information to manage disease in difficult-to-treat populations
  • •  Examination of treatment cost-effectiveness and barriers to treatment
  • •  Awareness of new therapeutic drugs, pharmacology of HCV therapy, and resistance to treatments

As we enter the third year of HEPATITIS C MANAGEMENT: STATE OF THE ART, enormous progress continues to be made in the treatment of this disease. A rapidly increasing number of treatment options require practitioners to continually update their knowledge about the potential benefits and pharmacology of various hepatitis C therapies. These therapies, as well as their side effects and effectiveness, make the decision to treat individual patients more complex. They require the practitioner to possess a sophisticated understanding of the natural history of the disease, viral resistance to therapy, and management requirements of various patient populations with hepatitis C.

Target Audience

The state-of-the art curriculum offered at this activity is designed to meet the needs of gastroenterologists, hepatologists, infectious disease specialists, HIV specialists, general practitioners, physician assistants, nurse practitioners, registered nurses, pharmacists and other frontline healthcare professionals involved in the management of patients with hepatitis C, including those with HCV/HIV coinfection.